Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Thursday, March 13th. Roth Capital analyst J.

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced Modulus ...

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

2. The company saw fourth quarter net sales grow 6.6% year over year, and full year sales leapt 60.6%. 3. Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company.

In a surprising move, Globus Medical announced the acquisition of Nevro Corp . (NYSE:NVRO) for $250 million. While initially met with investor skepticism, analysts view this deal as potentially ...

In a surprising move, Globus Medical announced the acquisition of Nevro Corp . (NYSE:NVRO) for $250 million. While initially met with investor skepticism, analysts view this deal as potentially ...

40 prospects, 9 tire kickers and 1 serious buyer, Globus Medical. Four years ago, Nevro was worth more than $5 billon. Globus is paying $250 million for Nevro, who, by the way, has about $290 million ...

2025 /PRNewswire/ -- The Ademi Firm is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click here to ...